ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes

INTRODUCTION: ROS1 oncogenic fusion, which was first identified by Rikova et al, is reported to be present in 1%–2% of non-small cell lung cancers (NSCLCs) and is defined as a distinct molecular sub-group. Crizotinib is very effective in ROS1-positive patients and is now Food and Drug Administration...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Amit, Pande, Nikhil, Noronha, Vanita, Patil, Vijay, Kumar, Rajiv, Chougule, Anuradha, Trivedi, Vaishakhi, Janu, Amit, Mahajan, Abhishek, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390829/
https://www.ncbi.nlm.nih.gov/pubmed/30915158
http://dx.doi.org/10.3332/ecancer.2019.900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390829/
https://www.ncbi.nlm.nih.gov/pubmed/30915158
http://dx.doi.org/10.3332/ecancer.2019.900

Ejemplares similares